Skip to main content
. 2023 Nov 21;12(24):21666–21679. doi: 10.1002/cam4.6724

FIGURE 5.

FIGURE 5

Analysis of the eosinophil proportion for each ICI and primary cancer type adjusted by propensity score matching. (A) Boxplot showing the eosinophil proportion in the baseline sample: non‐irAE (n = 210) and irAE (n = 216) groups. (B) Boxplot showing the eosinophil proportion in the two‐course sample; non–irAE (n = 206) and irAE (n = 214) groups. (C–E) Boxplot showing eosinophil proportion in a two‐course sample of patients who received (C) anti‐PD‐1 monotherapy (non‐irAE [n = 165] and irAE [n = 172] groups), (D) anti‐CTLA‐4 plus anti‐PD‐1 combination therapy (non‐irAE [n = 23] and irAE [n = 23] groups), and (E) anti‐PD‐L1 monotherapy (non‐irAE [n = 18] and irAE [n = 19] groups). (F–L) Boxplot showing eosinophil proportion in a two‐course sample of patients with (F) esophageal cancer (non‐irAE [n = 12] and irAE [n = 12] groups), (G) Gastric cancer (non‐irAE [n = 11] and irAE [n = 12] groups), (H) lung cancer (non‐irAE [n = 58] and irAE [n = 60] groups), (I) melanoma (non‐irAE [n = 19] and irAE [n = 22] groups), (J) renal cell carcinoma (non‐irAE [n = 35] and irAE [n = 38] groups), (K) urothelial carcinoma (non‐irAE [n = 32] and irAE [n = 34] groups), and (L) head and neck cancer (non‐irAE [n = 33] and irAE [n = 31] groups). The median value is represented by the horizontal midline in each box. The bottom and the top of each box are indicated. The 25th and 75th percentiles are represented by the ends of the whiskers, which indicate the minimum and maximum values of all data, respectively. *p < 0.05. (A–L) Unpaired t test. irAE, immune‐related adverse event; PD‐1, Programmed death 1; PD‐L1, Programmed death ligand 1.